This Article Full Text Full Text (PDF) All Versions of this Article: 35/9/2160    most recent 01.STR.0000138730.03264.acv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foerch, C. Articles by Sitzer, M. Search for Related Content PubMed PubMed Citation Articles by Foerch, C. Articles by Sitzer, M. Related Collections Other Stroke Treatment - Surgical Other diagnostic testing Acute Cerebral Infarction Brain Circulation and Metabolism Emergency treatment of Stroke

(Stroke. 2004;35:2160.)
© 2004 American Heart Association, Inc.

Original Contributions

Serum S100B Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery Occlusion

Christian Foerch, MD; Bettina Otto, MD; Oliver C. Singer, MD; Tobias Neumann-Haefelin, MD; Bernard Yan, MD; Joachim Berkefeld, MD; Helmuth Steinmetz, MD Matthias Sitzer, MD

From the Department of Neurology (C.F., B.O., O.C.S., T.N.-H., H.S., M.S.) and the Institute of Neuroradiology (B.Y., J.B.), Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Correspondence to Dr Christian Foerch, Department of Neurology, Johann Wolfgang Goethe-University Frankfurt am Main, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany. E-mail foerch{at}em.uni-frankfurt.de

Background and Purpose— Early predictors of infarct volume may improve therapeutic decisions in patients with acute cerebral ischemia. We investigated whether measurements of serum astroglial protein S100B can predict a malignant course of infarction in acute middle cerebral artery (MCA) occlusion.

Methods— We included 51 patients (24 women, mean age 69.1±12.4 years) admitted within 6 hours after stroke symptom onset caused by proximal MCA occlusion, as shown by magnetic resonance angiography (n=39), intra-arterial angiography (n=4), or transcranial duplex sonography (n=8). Blood samples were drawn at hospital admission and 8, 12, 16, 20, and 24 hours after symptom onset. Serum S100B concentrations were determined using a fully automated immunoluminometric assay. A malignant course of infarction was defined as the occurrence of clinical signs of cerebral herniation within the first 7 days of treatment or the clinical decision to perform decompressive hemicraniectomy caused by critical space-occupying swelling as detected by repeated neuroimaging.

Results— Sixteen patients developed malignant infarction (31%). Beginning with the 12-hour value, mean S100B serum concentrations were significantly higher in patients with a malignant course compared with those without (12 hours 1.23±1.24 versus 0.29±0.45 µg/L; 16 hours 1.80±1.65 versus 0.38±0.53 µg/L; 20 hours 1.90±1.53 versus 0.44±0.48 µg/L; and 24 hours 2.41±1.59 versus 0.57±0.66 µg/L; all P<0.001). A 12-hour S100B value >0.35 µg/L predicted malignant infarction with 0.75 sensitivity and 0.80 specificity. A 24-hour value >1.03 µg/L provided 0.94 sensitivity and 0.83 specificity.

Conclusions— The serum marker S100B can predict a malignant course of infarction in proximal MCA occlusion. This finding may improve the identification and monitoring of patients at particularly high risk for herniation.

Key Words: biological markers • brain edema • cerebral infarction • middle cerebral artery

This article has been cited by other articles:

				R. W. Y. Chan, C. A. Graham, T. H. Rainer, N. Y. L. Lam, R. W. K. Chiu, K.-W. Chik, V. Lee, and Y. M. D. Lo Use of a Bone Marrow Transplantation Model System to Demonstrate the Hematopoietic Origin of Plasma S100B mRNA Clin. Chem., October 1, 2007; 53(10): 1874 - 1876. [Full Text] [PDF]

				P. Delgado, J. Alvarez Sabin, E. Santamarina, C. A. Molina, M. Quintana, A. Rosell, and J. Montaner Plasma S100B Level After Acute Spontaneous Intracerebral Hemorrhage Stroke, November 1, 2006; 37(11): 2837 - 2839. [Abstract] [Full Text] [PDF]

				O. F. Laterza, V. R. Modur, D. L. Crimmins, J. V. Olander, Y. Landt, J.-M. Lee, and J. H. Ladenson Identification of Novel Brain Biomarkers Clin. Chem., September 1, 2006; 52(9): 1713 - 1721. [Abstract] [Full Text] [PDF]

				A. Jaramillo, F. Gongora-Rivera, J. Labreuche, J. -J. Hauw, and P. Amarenco Predictors for malignant middle cerebral artery infarctions: A postmortem analysis Neurology, March 28, 2006; 66(6): 815 - 820. [Abstract] [Full Text] [PDF]

				C Foerch, I Curdt, B Yan, F Dvorak, M Hermans, J Berkefeld, A Raabe, T Neumann-Haefelin, H Steinmetz, and M Sitzer Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 181 - 184. [Abstract] [Full Text] [PDF]

				H. Tomitori, T. Usui, N. Saeki, S. Ueda, H. Kase, K. Nishimura, K. Kashiwagi, and K. Igarashi Polyamine Oxidase and Acrolein as Novel Biochemical Markers for Diagnosis of Cerebral Stroke Stroke, December 1, 2005; 36(12): 2609 - 2613. [Abstract] [Full Text] [PDF]

				M. D. Hill Diagnostic Biomarkers for Stroke: A Stroke Neurologist's Perspective Clin. Chem., November 1, 2005; 51(11): 2001 - 2002. [Full Text] [PDF]